Last reviewed · How we verify
Middle Dose of MRM-3379 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Middle Dose of MRM-3379 (Middle Dose of MRM-3379) — Mirum Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Middle Dose of MRM-3379 TARGET | Middle Dose of MRM-3379 | Mirum Pharmaceuticals, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Middle Dose of MRM-3379 CI watch — RSS
- Middle Dose of MRM-3379 CI watch — Atom
- Middle Dose of MRM-3379 CI watch — JSON
- Middle Dose of MRM-3379 alone — RSS
Cite this brief
Drug Landscape (2026). Middle Dose of MRM-3379 — Competitive Intelligence Brief. https://druglandscape.com/ci/middle-dose-of-mrm-3379. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab